Security Snapshot

PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PTCT) Institutional Ownership

CUSIP: 69366J200

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

341

Shares (Excl. Options)

93,130,260

Price

$68.13

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
PTCT on Nasdaq
Shares outstanding
81,782,297
Price per share
$70.26
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
93,130,260
Total reported value
$6,343,724,262
% of total 13F portfolios
0%
Share change
+1,531,698
Value change
+$76,419,250
Number of holders
341
Price from insider filings
$70.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • PTCT - PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share is tracked under CUSIP 69366J200.
  • 341 institutions reported positions in Q1 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 347 to 341 between Q4 2025 and Q1 2026.
  • Reported value moved from $7,039,835,701 to $6,343,724,262.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 341 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 69366J200?
CUSIP 69366J200 identifies PTCT - PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Significant Owners of PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PTCT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% +85% $892,256,965 +$421,991,884 11,904,696 +90% BlackRock, Inc. 30 Nov 2025
JANUS HENDERSON GROUP PLC 8.7% +45% $494,116,913 +$160,878,918 7,193,433 +48% JANUS HENDERSON GROUP PLC 31 Mar 2026
ARMISTICE CAPITAL, LLC 6.9% -18% $269,133,425 -$46,705,135 5,434,843 -15% Armistice Capital, LLC 31 Mar 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.9% $331,883,645 4,871,329 Vanguard Portfolio Management 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $291,899,442 4,284,448 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 5.2% $326,100,949 4,206,126 STATE STREET CORPORATION 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 4.8% -23% $299,837,971 -$71,307,675 3,867,380 -19% Wellington Management Group LLP 31 Dec 2025
Camber Capital Management LP 4.2% $158,464,000 3,200,000 Camber Capital Management LP 31 Dec 2024
TORONTO DOMINION BANK 3.7% -30% $207,852,162 -$76,401,826 3,025,945 -27% The Toronto-Dominion Bank 31 Mar 2026

As of 31 Mar 2026, 341 institutional investors reported holding 93,130,260 shares of PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PTCT). This represents 114% of the company’s total 81,782,297 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PTCT) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 16% 12,948,717 +1.3% 0.02% $882,196,090
RTW INVESTMENTS, LP 9.5% 7,746,415 0% 5.3% $527,763,254
JANUS HENDERSON GROUP PLC 8.8% 7,193,433 +48% 0.24% $489,997,100
VANGUARD PORTFOLIO MANAGEMENT LLC 5.9% 4,804,594 0% 0.02% $327,336,989
STATE STREET CORP 5.3% 4,346,519 +3.3% 0.01% $296,128,339
WELLINGTON MANAGEMENT GROUP LLP 4.8% 3,942,610 +1.9% 0.05% $268,610,018
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 3,676,256 0% 0.01% $250,463,321
TORONTO DOMINION BANK 3.7% 3,025,963 -27% 0.4% $206,158,859
GEODE CAPITAL MANAGEMENT, LLC 2.7% 2,209,954 +9.6% 0.01% $150,589,658
ARMISTICE CAPITAL, LLC 2.5% 2,074,449 -26% 4.7% $141,332,210
Hood River Capital Management LLC 2% 1,664,559 +66% 1.1% $113,406,405
D. E. Shaw & Co., Inc. 2% 1,640,381 -6% 0.09% $111,759,157
FMR LLC 1.9% 1,528,362 -9.1% 0.01% $104,127,329
TANG CAPITAL MANAGEMENT LLC 1.8% 1,500,000 0% 5.2% $102,195,000
UBS Group AG 1.7% 1,364,768 +41% 0.02% $92,981,644
Jefferies Financial Group Inc. 1.7% 1,354,459 -18% 1.1% $92,279,292
Pictet Asset Management Holding SA 1.4% 1,183,720 +21% 0.08% $80,063,048
FRANKLIN RESOURCES INC 1.4% 1,121,388 -13% 0.02% $76,400,144
Driehaus Capital Management LLC 1.2% 1,015,772 -11% 0.51% $69,204,546
Palo Alto Investors LP 1.1% 921,607 +2% 9.6% $62,789,085
BNP PARIBAS FINANCIAL MARKETS 1.1% 920,476 0% 0.04% $62,712,030
DIMENSIONAL FUND ADVISORS LP 1.1% 890,715 +42% 0.01% $60,674,282
SG Americas Securities, LLC 1.1% 879,701 -1.7% 0.07% $59,934,000
Invesco Ltd. 1.1% 865,451 +99% 0.01% $58,963,177
GOLDMAN SACHS GROUP INC 1% 827,631 -19% 0.01% $56,386,500

Institutional Holders of PTC THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PTCT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 93,130,260 $6,343,724,262 +$76,419,250 $68.13 341
2025 Q4 92,674,477 $7,039,835,701 +$724,070,224 $75.96 347
2025 Q3 82,678,571 $5,073,764,701 +$181,615,186 $61.37 290
2025 Q2 79,911,059 $3,903,121,530 +$46,553,598 $48.84 281
2025 Q1 78,779,105 $4,025,030,193 +$67,568,904 $50.96 260
2024 Q4 77,719,633 $3,508,291,455 -$16,690,343 $45.14 237
2024 Q3 78,808,939 $2,925,502,301 -$38,880,960 $37.10 199
2024 Q2 79,829,985 $2,441,610,603 -$156,636,791 $30.58 196
2024 Q1 85,061,593 $2,474,579,740 +$22,339,643 $29.09 179
2023 Q4 84,601,340 $2,331,624,240 +$83,990,908 $27.56 169
2023 Q3 81,614,706 $1,828,981,040 -$51,055,249 $22.41 175
2023 Q2 81,025,132 $3,295,908,701 +$98,098,293 $40.67 201
2023 Q1 78,433,463 $3,798,260,033 +$90,684,481 $48.44 198
2022 Q4 76,981,862 $2,938,237,687 +$13,606,355 $38.17 196
2022 Q3 76,313,271 $3,830,944,634 +$86,495,993 $50.20 199
2022 Q2 74,083,474 $2,967,960,851 +$15,896,836 $40.06 171
2022 Q1 73,730,204 $2,750,879,876 -$34,162,193 $37.31 170
2021 Q4 75,095,879 $2,991,389,896 +$33,191,074 $39.83 166
2021 Q3 74,270,018 $2,763,598,375 +$31,311,987 $37.21 174
2021 Q2 73,830,496 $3,120,577,918 +$3,824,478 $42.27 174
2021 Q1 73,197,638 $3,466,689,095 +$45,849,603 $47.35 196
2020 Q4 72,827,805 $4,447,644,286 +$100,239,157 $61.03 205
2020 Q3 71,012,920 $3,320,619,406 +$114,326,210 $46.75 189
2020 Q2 68,359,820 $3,451,278,985 +$259,126,213 $50.74 198
2020 Q1 64,213,019 $2,865,901,646 +$125,294,621 $44.61 197
2019 Q4 61,124,372 $2,935,863,409 +$23,562,040 $48.03 203
2019 Q3 61,919,993 $2,094,320,996 +$114,605,453 $33.82 181
2019 Q2 58,378,537 $2,626,676,199 +$33,782,408 $45.00 173
2019 Q1 58,617,454 $2,206,343,369 +$373,569,818 $37.64 169
2018 Q4 48,764,141 $1,672,916,979 +$32,659,099 $34.32 160
2018 Q3 46,800,681 $2,199,661,172 +$196,122,715 $47.00 176
2018 Q2 42,887,283 $1,446,483,123 +$13,935,444 $33.73 164
2018 Q1 42,685,949 $1,154,889,575 +$143,231,958 $27.06 146
2017 Q4 38,109,969 $635,678,067 +$18,883,443 $16.68 119
2017 Q3 35,744,834 $715,228,449 +$44,754,005 $20.01 126
2017 Q2 33,526,261 $614,523,105 +$64,351,306 $18.33 111
2017 Q1 31,527,213 $310,226,812 +$57,103,339 $9.84 111
2016 Q4 28,676,672 $312,896,583 -$24,470,762 $10.91 117
2016 Q3 29,224,066 $409,245,732 +$31,590,430 $14.01 110
2016 Q2 28,567,042 $202,093,852 -$12,310,362 $7.02 113
2016 Q1 29,052,236 $187,275,624 -$209,529,061 $6.44 112
2015 Q4 36,309,263 $1,175,380,829 +$117,821,671 $32.40 141
2015 Q3 33,048,603 $881,940,071 -$17,562,428 $26.70 154
2015 Q2 32,610,815 $1,570,066,541 +$38,237,714 $48.13 152
2015 Q1 31,473,162 $1,915,082,191 +$210,644,324 $60.85 157
2014 Q4 28,362,106 $1,468,602,926 +$198,969,370 $51.77 131
2014 Q3 24,376,802 $1,072,967,175 +$75,631,280 $44.01 99
2014 Q2 22,967,349 $600,370,273 +$12,312 $26.14 83
2014 Q1 22,954,586 $600,024,825 +$219,416,366 $26.14 63
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .